Merlintrader’s Daily Briefing

Tuesday, July 14, 2026 — evening wrap. Wall Street shook off the morning’s risk-off tone and finished higher after a cooler-than-expected June inflation report eased Fed rate-hike fears. The S&P 500 rose 0.38% to 7,543.59, the Nasdaq Composite added 0.9% to 26,107.01 and the Dow edged up 9.63 points (+0.02%) to 52,508.27, with semiconductors leading and strong big-bank earnings offsetting a roughly 25% collapse in IBM. Crude stayed firmly bid as the U.S. reimposed its blockade on Iran.

Wall Street: Tuesday’s close
  • Close— The S&P 500 rose 0.38% to 7,543.59, the Nasdaq Composite gained 0.9% to 26,107.01 and the Dow added 9.63 points (+0.02%) to 52,508.27.Indices
  • Comeback— Indexes reversed a lower open, with the S&P and Nasdaq clawing back Monday’s losses as the soft CPI print reset rate expectations.Reversal
  • Semis— Chip stocks led the advance, rebounding from the memory-driven selloff that had dominated the prior session.Chips
Cooler CPI resets the tape
  • Headline— June CPI rose 3.5% year over year, below the roughly 3.8% consensus and matching the lowest annual pace since 2020.Macro
  • Monthly— Prices fell a seasonally adjusted 0.4% on the month, an unexpectedly strong decline led by lower gasoline.Macro
  • Read— The soft print cooled Fed rate-hike bets and gave growth and rate-sensitive names room to rally.Rates
Big banks kick off Q2
  • JPMorgan— Adjusted EPS of $6.14 topped the $5.85 estimate on revenue of $52.42B versus $50.19B expected; shares rose about 2%.Earnings
  • Citigroup— EPS of $3.15 beat $2.74 on $24.77B revenue as profit jumped about 45% on investment-banking and trading strength, but shares slipped about 2% on expense worries.Earnings
  • BofA & Goldman— Bank of America gained nearly 2% on its beat, while Goldman Sachs flagged fees from the SpaceX IPO; trading desks benefited from the geopolitical volatility.Earnings
IBM cracks
  • IBM— Shares plunged roughly 25% after an earnings warning, as enterprise clients shift spending away from software and mainframes toward AI infrastructure.Tech
Oil and Hormuz
  • WTI— U.S. crude settled up about 1.5% at $79.34 a barrel, extending the prior session’s spike.Oil
  • Brent— The international benchmark rose about 1.7% to $84.73 as the Gulf risk premium held.Oil
  • Escalation— The U.S. launched fresh airstrikes on Iran and reimposed a blockade on its ports at 4 p.m. ET; President Trump dropped his earlier demand for a 20% fee on cargo transiting the Strait of Hormuz.Geopolitics
Merlintrader verticals
  • AI & semis— The chip rebound and IBM’s AI-infrastructure comments underscored the market’s ongoing rotation toward AI hardware.AI
  • Energy & uranium— Energy names tracked the crude premium; uranium and energy stay sensitive to every Hormuz headline.Energy
  • Defense & space— Defense and space names stay tied to how the blockade and any further strikes evolve.Defense
  • Biotech— The out-of-favor biotech group remains a recovery watch; confirm any PDUFA date or trial readout on official FDA and company sources before treating it as set.Biotech
Bottom line
  • First read— A cooler June CPI flipped the tone, lifting stocks off the morning lows and easing rate-hike fears.Bottom Line
  • Second read— Big-bank earnings were strong across the board, though Citi’s expense worries and IBM’s warning showed dispersion under the surface.Bottom Line
  • Third read— Oil stayed firmly bid on the renewed Iran escalation, keeping energy and geopolitics the key swing factor into the rest of the week.Bottom Line
Read the full Daily Briefing
Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: July 14 → September 30, 2026. Compact homepage board for FDA decisions, advisory committees, regulatory submissions and major clinical readouts. October and later events are excluded from this widget.

39Active
21FDA / Reg
18Data / Filing
Jul 14Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$CELCgedatolisibJul 17PDUFA HR+/HER2- breast cancer

Celcuity. NDA PDUFA for gedatolisib in HR+/HER2-, PIK3CA wild-type advanced breast cancer. Priority Review makes this one of the nearest important small/mid-cap oncology binaries.

$MNKDFUROSCIX ReadyFlowJul 26sNDA Autoinjector / edema

MannKind. PDUFA for the FUROSCIX ReadyFlow autoinjector sNDA for edema in adults with chronic heart failure or chronic kidney disease.

$OTLKLYTENAVAJul 29Risk Wet AMD resubmission

Outlook Therapeutics. Class 1 resubmitted BLA PDUFA for LYTENAVA / ONS-5010 in wet AMD. Prior FDA rejection history keeps this high risk.

$CAPRderamiocel panelJul 29AdCom Panel before Aug PDUFA

Capricor. FDA advisory committee for deramiocel in Duchenne muscular dystrophy cardiomyopathy. Panel tone and briefing documents are the key pre-PDUFA read-through.

$REPLRP1 panelJul 30AdCom Melanoma panel review

Replimune. FDA advisory committee for RP1 plus nivolumab in advanced melanoma after anti-PD-1 therapy. Single-arm evidence risk remains central.

$REPLRP1Aug 2PDUFA Melanoma BLA resubmission

Replimune. BLA resubmission goal date for RP1. This is a very compressed AdCom-to-PDUFA setup with elevated regulatory risk.

$MRNAmFLUSIVAAug 5PDUFA mRNA seasonal flu

Moderna. BLA PDUFA for mRNA seasonal flu vaccine candidate in adults 50+. More platform and lifecycle read-through than pure small-cap binary.

$REGNgaretosmabAugFDA FOP ultra-rare disease

Regeneron. BLA target action month for garetosmab in adult fibrodysplasia ossificans progressiva. Month-only calendar item.

$LNTHMK-6240Aug 13NDA Tau PET imaging

Lantheus. NDA PDUFA for MK-6240 tau PET imaging in Alzheimer’s disease. Diagnostic/imaging catalyst, not a therapeutic efficacy binary.

$CAPRderamiocelAug 22PDUFA DMD cardiomyopathy

Capricor. BLA PDUFA for deramiocel in Duchenne muscular dystrophy cardiomyopathy. Prior CRL history and July AdCom make this highly binary.

$RAREDTX401Aug 23BLA GSDIa gene therapy

Ultragenyx. Priority Review BLA PDUFA for DTX401 in glycogen storage disease type Ia. First of two near-term Ultragenyx gene-therapy decisions.

$BIIBLeqembi IQLIKAug 24sBLA SC starting dose

Biogen / Eisai. sBLA PDUFA for once-weekly subcutaneous Leqembi starting-dose use. Large-cap Alzheimer’s lifecycle catalyst.

$JAZZZiihera comboAug 25sBLA 1L HER2+ GEA

Jazz Pharmaceuticals. sBLA PDUFA for Ziihera combination use in first-line HER2-positive gastroesophageal adenocarcinoma.

$GILDBIC/LENAug 27NDA Once-daily HIV regimen

Gilead. NDA PDUFA for bictegravir/lenacapavir in virologically suppressed adults. Strategic HIV franchise catalyst.

$PTGXrusfertideQ3PDUFA Polycythemia vera

Protagonist / Takeda. Priority Review NDA window for rusfertide in polycythemia vera. Exact date not pinned in this compact board.

$NUVLzidesamtinibSep 18NDA ROS1+ NSCLC

Nuvalent. NDA PDUFA for zidesamtinib in ROS1-positive non-small-cell lung cancer. Important targeted-oncology regulatory event.

$RAREUX111Sep 19Risk Sanfilippo A gene therapy

Ultragenyx. Resubmitted BLA PDUFA for UX111 in Sanfilippo syndrome type A. CMC and facility risk remain the key swing factors.

$IONSzilganersenSep 22NDA Alexander disease

Ionis. NDA PDUFA for zilganersen in Alexander disease. Rare neurological disease Priority Review event.

$BFRIAmeluz PDTSep 28sNDA Superficial BCC expansion

Biofrontera. PDUFA for Ameluz photodynamic therapy sNDA seeking expansion into superficial basal cell carcinoma. Small-cap liquidity can amplify reaction.

$SRRKapitegromabSep 30BLA Spinal muscular atrophy

Scholar Rock. BLA PDUFA for apitegromab in spinal muscular atrophy. Manufacturing and fill-finish facility status remain key watch items.

$ROIVbrepocitinibQ3NDA Dermatomyositis

Priovant / Roivant. NDA Priority Review window for brepocitinib in dermatomyositis. Company has pointed to potential launch timing by end-September if approved.

$QUREAMT-130Q3BLA Huntington’s AA path

uniQure. Planned BLA submission for AMT-130 in Huntington’s disease. Not a PDUFA, but one of the most important regulatory-pathway events in the quarter.

$SLNdivesiranAugData SANRECO Phase 2 PV

Silence Therapeutics. SANRECO Phase 2 topline data for divesiran in polycythemia vera. Important read-through alongside $PTGX / Takeda rusfertide.

$IMMXNXC-201Q3Data AL amyloidosis

Immix Biopharma. NEXICART-2 topline data for NXC-201 in relapsed/refractory AL amyloidosis. BLA-enabling study, high-volatility small-cap setup.

$KPTIselinexorNearData Endometrial cancer Ph3

Karyopharm. XPORT-EC-042 Phase 3 topline data for selinexor in endometrial cancer. Treat as near-term until released or formally delayed.

$KODDAYBREAKQ3Data Wet AMD Phase 3

Kodiak Sciences. DAYBREAK Phase 3 topline data for tarcocimab / KSI-501 in wet AMD. Watch efficacy, durability, dosing interval and safety.

$ALMSenvudeucitinibQ3Data SLE Phase 2b

Alumis. LUMUS Phase 2b readout for envudeucitinib in systemic lupus erythematosus. Autoimmune data can be noisy; dose response matters.

$IVVDVYD2311Q3Data DECLARATION pivotal

Invivyd. DECLARATION pivotal / Phase 3 topline data for VYD2311. COVID-antibody sentiment can be unstable, but pivotal data can still move the name.

$MPLTML-007C-MAMid-AugData ZEPHYR schizophrenia Ph2

MapLight Therapeutics. Phase 2 ZEPHYR topline results for ML-007C-MA in schizophrenia. CNS readout with potentially sharp binary reaction.

$AMLXavexitideQ3Ph3 PBH pivotal LUCIDITY

Amylyx. Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia. One of the clearest Phase 3 clinical binaries of the quarter.

$PHVSdeucrictibant ERQ3Ph3 HAE prophylaxis Ph3

Pharvaris. Phase 3 CHAPTER-3 data for extended-release deucrictibant as prophylaxis for hereditary angioedema. Major HAE readout.

$SYRESPY003Q3Data IBD / UC Phase 2

Spyre Therapeutics. Phase 2 SKYLINE Part A topline data for SPY003 in inflammatory bowel disease and ulcerative colitis.

$VERATrutakna / ataciceptQ3eGFR ORIGIN 3 follow-up

Vera Therapeutics. ORIGIN 3 eGFR analysis following accelerated approval. Not another approval decision, but important for durability and confirmatory confidence.

$OCGNOCU410STQ3Data Stargardt interim analysis

Ocugen. Interim OCU410ST analysis after 24 patients complete eight months of follow-up in Stargardt disease. Small-cap ophthalmology catalyst.

$XENEazetukalnerQ3NDA Focal-onset seizures filing

Xenon. Expected NDA submission for azetukalner in focal-onset seizures. Filing confirmation would set up future FDA acceptance and PDUFA timing.

$BBIOinfigratinibQ3NDA Achondroplasia filing

BridgeBio. Expected NDA submission for infigratinib in achondroplasia. Submission timing and acceptance will define the next regulatory leg.

$CLNNCNM-Au8Q3NDA ALS accelerated pathway

Clene. Targeted NDA submission for CNM-Au8 in ALS through an accelerated pathway. Very high regulatory strategy risk because submission does not guarantee acceptance.

$OCGNOCU400Q3BLA Rolling BLA start

Ocugen. Expected start of rolling BLA submission for OCU400 in retinitis pigmentosa. Filing progress, manufacturing and future acceptance are the next watch items.

$MLTXsonelokimabLate SepBLA HS filing watch

MoonLake. Planned BLA submission for sonelokimab in hidradenitis suppurativa around the end of September. Acceptance would create the next formal FDA calendar item.

Most attention-worthy watchlist

$CELC$OTLK$REPL$CAPR$RARE$NUVL$IONS$SRRK$AMLX$PHVS$QURE$MPLT

Board rule

Only July–September catalysts are shown. October and later events are intentionally excluded from this compact homepage widget. Resolved decisions are removed from the active board: $SNY Sarclisa SC was approved on July 10, ahead of its original July 23 target date. Events with only Q3 guidance are included, but should be rechecked against company filings before trading around them.

Educational content only — not investment advice. Verify dates and filings before trading around binary events. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with CONSOB (Italy) and SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.

Avvertenza. Questo contenuto ha finalità esclusivamente didattiche e informative. Non costituisce consulenza finanziaria né una raccomandazione di acquisto o vendita di alcun titolo, in linea con le indicazioni CONSOB (Italia) e SEC (USA). I dati sono generati dall'AI a partire da fonti web e possono contenere errori o non essere aggiornati — verifica sempre rispetto alla fonte primaria collegata. Fai le tue ricerche e consulta un consulente autorizzato. Disclaimer completo: merlintrader.com/disclaimer.